David A. Siegel Lumos Pharma, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.64 - $3.22 $9,504 - $11,592	3,600 Added 12.72%	31,900 $89,000
Q4 2023 Feb 14, 2024	BUY	$2.81 - $4.27 $79,523 - $120,840	28,300 New	28,300 $89,000
Q1 2021 May 17, 2021	SELL	$11.58 - $31.11 $85,668 - $230,151	-7,398 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$13.61 - $35.91 $73,494 - $193,913	-5,400 Reduced 42.19%	7,398 $264,000
Q3 2020 Nov 16, 2020	SELL	$13.25 - $16.5 $6,625 - $8,250	-500 Reduced 3.76%	12,798 $177,000
Q2 2020 Aug 14, 2020	SELL	$7.76 - $16.99 $5,432 - $11,892	-700 Reduced 5.0%	13,298 $219,000
Q1 2020 May 15, 2020	BUY	$0.89 - $8.85 $12,458 - $123,882	13,998 New	13,998 $119,000

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.